CLYM — Climb Bio, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1768446 ·
Last close
$9.78
Market Cap
$574.46M
52W High
$18.33
52W Low
$1.63
ADV30
1,169,835
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -16,893,000 -14,573,000 236,564,000 39,731,000 8,511,000
Jun 2026 0 — -15,359,000 -13,498,000 246,294,000 44,107,000 6,747,000
Mar 2026 0 — -15,211,000 -13,722,000 152,372,000 8,356,000 4,287,000
Dec 2025 0 — -19,296,000 -17,516,000 167,744,000 35,685,000 7,269,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-52,560,000
Investing CF
$-38,280,000
Financing CF
$104,911,000
CapEx
$-929,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.82
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-331,520,000
Inventory
—
Receivables
$1,366,000
ST Investments
$165,692,000
EBIT TTM
$-66,759,000
Pretax Income TTM
$-59,309,000
Interest Exp TTM
—
Analysts
15

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -67,883,000 -59,851,000 167,744,000 7,269,000 160,475,000 -54,356,000
Dec 2024 0 -30,361,000 -73,897,000 217,187,000 5,306,000 211,881,000 -15,562,000
Dec 2023 0 -40,275,000 -35,119,000 110,469,000 2,870,000 107,599,000 -20,599,000
Dec 2022 0 -45,135,000 -45,244,000 134,992,000 6,277,000 128,715,000 -37,369,000

TTM Snapshot

Revenues TTM
$9,519,000
NetIncome TTM
$-57,624,000
OpCashFlow TTM
—
Assets (Latest)
$246,294,000
Forward EPS
$-1.00

Peers — same industry

TickerNameMarket CapLastDaily %
WVE Wave Life Sciences, Inc. $560.13M $2.84 —
ZVRA ZEVRA THERAPEUTICS, INC. $559.34M $9.40 —
EVOTF Evotec SE $590.83M $3.33 —
ANL Adlai Nortye Group Ltd. $556.80M $9.48 —
AVBP ArriVent BioPharma, Inc. $552.92M $10.69 —

News headlines (Yahoo Finance, 1h cache)

Wedbush keeps Climb Bio on Best Ideas List, raises price target
2026-11-06 16:58 · Yahoo
Climb Bio Reports Third Quarter 2026 Financial Results and Provides Business Updates
2026-11-05 12:00 · Yahoo
Wedbush Says This Stock Remains a Top Pick Despite Recent Volatility
2026-11-04 16:24 · Yahoo
Climb Bio to Present New Data for Budoprutug in Immune Thrombocytopenia at the 68th American Society of Hematology Annual Meeting and Exposition
2026-11-04 14:00 · Yahoo
Climb Bio to Present at Guggenheim 3rd Annual Healthcare Innovation Conference
2026-11-02 12:00 · Yahoo
Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026
2026-10-24 23:30 · Yahoo
Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026
2026-10-23 20:01 · Yahoo
Deutsche Bank starts Climb Bio at Buy, citing compelling autoimmune pipeline
2026-10-20 15:14 · Yahoo
Are Medical Stocks Lagging Climb Bio, Inc. (CLYM) This Year?
2026-10-20 12:40 · Yahoo
Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug
2026-10-02 13:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.